Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion® Transdermal Delivery Device

Expands Patent Portfolio for its Contraceptive Patch, Twirla™

PRINCETON, N.J., June 20, 2014 -- Agile Therapeutics, Inc., (AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that patent U.S. 8,747,888 ('888 Patent), was issued by the U.S. Patent and Trademark Office on June 10, 2014. The patent is a continuation of its prior patent US 8,246,978 and is intended to provide additional patent protection covering its contraceptive patch, Twirla™ ethinyl estradiol and levonorgestrel transdermal system.

Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug

Cara Therapeutics Initiates Further Phase 1a/1b Trial of Enteris' Tablet Formulation of Oral CR845 Following Successful Initial Phase 1 Study

BOONTON, N.J., June 20, 2014 -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. 

The tablet formulation of oral CR845 was formulated utilizing Enteris' proprietary oral delivery technology under a Manufacturing and Clinical Supply Agreement.  The agreement with Cara Therapeutics is representative of Enteris' broader "Feasibility-to-Licensing" strategy involving its peptide and small molecule oral drug delivery platform.

Zafgen, Inc. Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., June 18, 2014  -- Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $16.00 per share, before underwriting discounts. All of the common stock is being offered by Zafgen. In addition, Zafgen has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market on June 19, 2014 under the symbol "ZFGN."